Zai Lab Ltd (ZLAB NASDAQ) stock market data APIs
$33.3176
-0.12(-0.4%)
as of September 18, 2025
Try our APIs with
free plan!
Zai Lab Ltd Financial Data Overview
Price chart is built with
Anychart
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is headquartered in Pudong, China.
Prev. Close
33.3176
Open
33.1947
High
33.2107
Low
32.2764
52 wk Range
20.17-44.34
Market Cap
3 625 M
Shares Outstanding
111 M
Revenue
428 M
EPS
-0.04
Beta
1.035
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Zai Lab Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Zai Lab Ltd data using free add-ons & libraries
Get Zai Lab Ltd Fundamental Data
Zai Lab Ltd Fundamental data includes:
- Net Revenue: 428 M
- EBITDA: -233 854 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.41
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Zai Lab Ltd News
New
Zai Lab Limited (ZLAB): A Bull Case Theory
We came across a bullish thesis on Zai Lab Limited on Value investing subreddit by mrmrmrj. In this article, we will summarize the bulls’ thesis on ZLAB. Zai Lab Limited's share was trading at $30...
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
Biotech stocks Zai Labs and BeOne Medicines plummeted Wednesday on reports President Donald Trump will issue an executive order to reduce U.S. access to drugs developed in China. Continue Reading View Comments
Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
Asian equities traded in the US as American depositary receipts were tracking higher Wednesday morni PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Institutional investors may overlook Zai Lab Limited's (NASDAQ:ZLAB) recent US$260m market cap drop as long-term gains remain positive
Key Insights Given the large stake in the stock by institutions, Zai Lab's stock price might be vulnerable to their trading decisions 51% of the business is held by the top 10 shareholders Ownership ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
